Recombinant Human HER1/ERBB1/EGFR Protein
Sizes: 10ug, 20g, 50ug, 100ug
Catalogue Numbers: RP00210-10, RP00210-20, RP00210-50, RP00210-100
Citations, Manuals and MSDS Available upon request.
Description: Recombinant Human HER1/ERBB1/EGFR Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Met1-Ser645) of human EGFR (Accession #NP_005219.2. ) fused with a 6×His tag at the C-terminus.
Alternate Names: EGFR, ERBB, ERBB1, HER1, NISBD2, PIG61, mENA, epidermal growth factor receptor, ERBB, ERBB1, HER1, NISBD2, PIG61, mENA
SWISS: P00533
GeneID: 1956
Species: Human
Purity: ≥ 90 % as determined by SDS-PAGE.
Storage: Store at -20 ℃. Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
Background: The EGFR (epidermal growth factor receptor) subfamily of receptor tyrosine kinases comprises four members: EGFR (also known as HER-1, ErbB1, or ErbB), ErbB2 (Neu, HER-2), ErbB3 (HER-3), and ErbB4 (HER-4). EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc.The human EGFR cDNA encodes a 1210 amino acid (aa) precursor with a 24 aa signal peptide, a 621 aa extracellular domain (ECD), a 23 aa transmembrane segment, and a 542 aa cytoplasmic domain. EGFR signaling has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently, which is overexpressed in a wide variety of tumors and is the target of several anti-cancer drugs.
Bio-Activity: Measured by its binding ability in a functional ELISA. Immobilized Human EGFR at 5 μg/mL (100 μL/well) can bind Human EGF with a linear range of 7-25 ng/mL.
Source: HEK293 cells
Tag: C-His
Formulation: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation.
Antigen Sequence: MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPS
Endotoxin: < 0.1 EU/μg of the protein by LAL method.
Research Use Only